GlassScriptPhysician profile
Salil J Patel
NPI 1346236510
$5,592.15
in general payments reported to CMS, 2019-2025
31 companies · $765 in 2025
The $765 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $1,509 · 2021: $1,069 · 2022: $487 · 2023: $257 · 2024: $624 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.82 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,781.86 | 2019-2021 | |
| Amgen INC. | $593.86 | 2019-2025 | Repatha, Repatha |
| Siemens Medical Solutions USA, INC. | $352.98 | 2020-2022 | |
| Pfizer INC. | $317.85 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $282.41 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $269.65 | 2023-2025 | Lokelma, Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $260.06 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $235.26 | 2019-2024 | Watchman Flx |
| Abbott Laboratories | $225.38 | 2022-2025 | Esprit, Amplatzer Talisman, Thoratec Heartmate 3 Lvas Implant Kit |
| Heartflow, INC. | $213.22 | 2025 | |
| Scpharmaceuticals INC. | $172.30 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $106.24 | 2023-2025 | Verquvo |
| Travere Therapeutics, INC. | $90.72 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.64 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $85.02 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $83.47 | 2024-2025 | |
| Cvrx, INC. | $68.05 | 2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $53.72 | 2022-2025 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $52.84 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $37.56 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $37.35 | 2024 | |
| Atricure, INC. | $35.86 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Vital Connect, INC | $23.05 | 2024 | Vitalpatch Rtm |
| Esperion Therapeutics, INC. | $22.53 | 2025 | Nexletol |
| Mannkind Corporation | $21.42 | 2025 | |
| Edwards Lifesciences Corporation | $19.02 | 2019 | |
| Novo Nordisk INC | $15.55 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $15.10 | 2025 | Arexvy, Shingrix |
| Medtronic, INC. | $13.55 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.21 | 2020 | |
| Vivaquant INC, Dba Rhythm Express | $7.42 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.